Coronavirus Infections
Conditions
Keywords
Biobank, SARS-CoV-2, COVID-19
Brief summary
Establishment of a biological bank of subjects vaccinated against SARS-Cov-2 infection (COVID-BioVac)
Detailed description
The purpose of the COVID-BioVac study is to establish a biobank of biological samples from subjects who have received the anti-SARS-CoV-2 vaccine, with the ultimate aim (following approval by the EC of specific substudies) to study and characterize the antiviral immune response generated following anti-SARS-CoV-2 vaccination. To this end, the COVID-BioVac Biobank will be officially established for the collection and storage of human biological material, non-profit, to support research activities aimed at advancing scientific knowledge, including in the genetic field, on the immune response. vaccination-induced anti-SARS-CoV-2.
Interventions
OTHERbiological bank
biological bank of subjects vaccinated against SARS-CoV-2 infection
Sponsors
IRCCS San Raffaele
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age ≥18 years * Who have vaccinated for SARS-CoV-2 with Pfizer-BioNTech vaccine or others * Signing of informed consent from January to March 2021
Exclusion criteria
* none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| COVID-19 vaccines response | from Day 1 of first vaccination up to 1 years after the last vaccination | Create a Biobank to evaluate the immunogenicity of COVID-19 vaccines in terms of antibody titers |
Countries
Italy
Outcome results
None listed